Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market has experienced rapid expansion in recent years. This market is expected to increase from $3.18 billion in 2025 to $3.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.2%. Historically, this growth has been driven by factors including the rising prevalence of obesity, the increasing incidence of type 2 diabetes, growing awareness of liver health disorders, the expansion of diagnostic testing capabilities, and the early adoption of lifestyle modification programs.
The metabolic dysfunction-associated steatohepatitis (mash) treatment market is poised for significant expansion over the upcoming years. It is projected to reach $8.6 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 22.0%. This anticipated growth during the forecast period stems from factors such as the increasing uptake of glp-1 agonists, advancements in antifibrotic drug development, a rise in the penetration of digital liver monitoring tools, the broadening use of bariatric surgery, and an intensified focus on personalized metabolic therapies. Key trends within this forecast timeframe encompass the expansion of precision liver disease therapeutics, AI-enabled early detection and risk stratification, cloud-based liver health data management, iot-integrated lifestyle and medication monitoring, and the progression of sustainable and preventive metabolic health programs.
Get A Free Sample Report With In-Depth Market Insights:
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Expansion Drivers: What’s Shaping Future Growth?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market is anticipated to expand due to the rising occurrence of obesity. Obesity is identified as a medical condition where excessive body fat accumulates, negatively impacting overall health, typically indicated by a body mass index (BMI) of 30 or higher. The global prevalence of obesity is on the rise, influenced by sedentary lifestyles, unhealthy eating habits, and metabolic risk factors. Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment, when related to obesity, focuses on tackling insulin resistance, decreasing liver fat, and enhancing metabolic health through lifestyle adjustments and targeted therapies. For instance, in March 2023, the World Heart Foundation, a Switzerland-based non-government global cardiovascular community, stated that approximately 2.3 billion adults and children worldwide are currently obese or overweight, with this number projected to reach 2.7 billion by 2025, considering the ongoing obesity trend. Therefore, the increasing prevalence of obesity is a key driver for growth within the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segment Performance And Emerging Opportunities
The metabolic dysfunction-associated steatohepatitis (mash) treatment market covered in this report is segmented –
1) By Treatment: Drug, Therapy
2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Strategic Trends: What Defines The Next Growth Phase?
Major companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focused on developing innovative products, specifically liver fibrosis treatment solutions, to offer options for patients with MASH and moderate to severe liver fibrosis. These solutions are designed to address the underlying causes of liver damage through lifestyle changes, antiviral medications, and emerging antifibrotic therapies, intending to halt or reverse fibrosis progression and enhance liver function. For instance, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom). This marks the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra, a daily oral tablet, demonstrated its effectiveness in resolving MASH without worsening fibrosis and improved liver fibrosis in phase 3 clinical trials. This advancement provides a non-invasive treatment alternative, eliminating the need for liver biopsies, and significantly enhances patient access and outcomes in managing fatty liver disease.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA
View The Full Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report:
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (mash) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
